Your browser doesn't support javascript.
loading
Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.
Nataraj, Nishanth Belugali; Noronha, Ashish; Lee, Joo Sang; Ghosh, Soma; Mohan Raju, Harsha Raj; Sekar, Arunachalam; Zuckerman, Binyamin; Lindzen, Moshit; Tarcitano, Emilio; Srivastava, Swati; Selitrennik, Michael; Livneh, Ido; Drago-Garcia, Diana; Rueda, Oscar; Caldas, Carlos; Lev, Sima; Geiger, Tamar; Ciechanover, Aaron; Ulitsky, Igor; Seger, Rony; Ruppin, Eytan; Yarden, Yosef.
Afiliação
  • Nataraj NB; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Noronha A; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Lee JS; Cancer Data Science Lab, National Cancer Institute, NIH, Rockville, MD, USA.
  • Ghosh S; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Mohan Raju HR; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Sekar A; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Zuckerman B; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Lindzen M; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Tarcitano E; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Srivastava S; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Selitrennik M; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Livneh I; Technion Integrated Cancer Center (TICC) and the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
  • Drago-Garcia D; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Rueda O; Cancer Research UK Cambridge Institute, University of Cambridge and the Cambridge Cancer Centre, Department of Oncology, Cambridge, UK.
  • Caldas C; Cancer Research UK Cambridge Institute, University of Cambridge and the Cambridge Cancer Centre, Department of Oncology, Cambridge, UK.
  • Lev S; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Geiger T; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Ciechanover A; Technion Integrated Cancer Center (TICC) and the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
  • Ulitsky I; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Seger R; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Ruppin E; Cancer Data Science Lab, National Cancer Institute, NIH, Rockville, MD, USA.
  • Yarden Y; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. Electronic address: yosef.yarden@weizmann.ac.il.
Cell Rep ; 38(8): 110418, 2022 02 22.
Article em En | MEDLINE | ID: mdl-35196484
ABSTRACT
By establishing multi-omics pipelines, we uncover overexpression and gene copy-number alterations of nucleoporin-93 (NUP93), a nuclear pore component, in aggressive human mammary tumors. NUP93 overexpression enhances transendothelial migration and matrix invasion in vitro, along with tumor growth and metastasis in animal models. These findings are supported by analyses of two sets of naturally occurring mutations rare oncogenic mutations and inactivating familial nephrotic syndrome mutations. Mechanistically, NUP93 binds with importins, boosts nuclear transport of importins' cargoes, such as ß-catenin, and activates MYC. Likewise, NUP93 overexpression enhances the ultimate nuclear transport step shared by additional signaling pathways, including TGF-ß/SMAD and EGF/ERK. The emerging addiction to nuclear transport exposes vulnerabilities of NUP93-overexpressing tumors. Congruently, myristoylated peptides corresponding to the nuclear translocation signals of SMAD and ERK can inhibit tumor growth and metastasis. Our study sheds light on an emerging hallmark of advanced tumors, which derive benefit from robust nucleocytoplasmic transport.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Complexo de Proteínas Formadoras de Poros Nucleares Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Complexo de Proteínas Formadoras de Poros Nucleares Idioma: En Ano de publicação: 2022 Tipo de documento: Article